99 related articles for article (PubMed ID: 15756681)
1. Clinicopathologic and prognostic values of apolipoprotein D alterations in hepatocellular carcinoma.
Utsunomiya T; Ogawa K; Yoshinaga K; Ohta M; Yamashita K; Mimori K; Inoue H; Ezaki T; Yoshikawa Y; Mori M
Int J Cancer; 2005 Aug; 116(1):105-9. PubMed ID: 15756681
[TBL] [Abstract][Full Text] [Related]
2. Methylation of IRAK3 is a novel prognostic marker in hepatocellular carcinoma.
Kuo CC; Shih YL; Su HY; Yan MD; Hsieh CB; Liu CY; Huang WT; Yu MH; Lin YW
World J Gastroenterol; 2015 Apr; 21(13):3960-9. PubMed ID: 25852282
[TBL] [Abstract][Full Text] [Related]
3. Epidermal growth factor-containing fibulin-like extracellular matrix protein 1, EFEMP1, a novel tumor-suppressor gene detected in hepatocellular carcinoma using double combination array analysis.
Nomoto S; Kanda M; Okamura Y; Nishikawa Y; Qiyong L; Fujii T; Sugimoto H; Takeda S; Nakao A
Ann Surg Oncol; 2010 Mar; 17(3):923-32. PubMed ID: 19898900
[TBL] [Abstract][Full Text] [Related]
4. DNA methylation profiling identifies EYA4 gene as a prognostic molecular marker in hepatocellular carcinoma.
Hou X; Peng JX; Hao XY; Cai JP; Liang LJ; Zhai JM; Zhang KS; Lai JM; Yin XY
Ann Surg Oncol; 2014 Nov; 21(12):3891-9. PubMed ID: 24306662
[TBL] [Abstract][Full Text] [Related]
5. Predictive value of expression and promoter hypermethylation of XAF1 in hepatitis B virus-associated hepatocellular carcinoma treated with transplantation.
Zhang F; Wu LM; Zhou L; Chen QX; Xie HY; Feng XW; Zheng SS
Ann Surg Oncol; 2008 Dec; 15(12):3494-502. PubMed ID: 18830757
[TBL] [Abstract][Full Text] [Related]
6. Identification of the A kinase anchor protein 12 (AKAP12) gene as a candidate tumor suppressor of hepatocellular carcinoma.
Hayashi M; Nomoto S; Kanda M; Okamura Y; Nishikawa Y; Yamada S; Fujii T; Sugimoto H; Takeda S; Kodera Y
J Surg Oncol; 2012 Mar; 105(4):381-6. PubMed ID: 22052684
[TBL] [Abstract][Full Text] [Related]
7. Methylation of Tip30 promoter is associated with poor prognosis in human hepatocellular carcinoma.
Lu B; Ma Y; Wu G; Tong X; Guo H; Liang A; Cong W; Liu C; Wang H; Wu M; Zhao J; Guo Y
Clin Cancer Res; 2008 Nov; 14(22):7405-12. PubMed ID: 19010857
[TBL] [Abstract][Full Text] [Related]
8. Expression analysis of THOP1 in background liver, a prognostic predictive factor in hepatocellular carcinoma, extracted by multiarray analysis.
Nomoto S; Hishida M; Inokawa Y; Takano N; Kanda M; Nishikawa Y; Fujii T; Koike M; Sugimoto H; Kodera Y
Ann Surg Oncol; 2014 Jun; 21 Suppl 3():S443-50. PubMed ID: 24604581
[TBL] [Abstract][Full Text] [Related]
9. Identification of intragenic methylation in the TUSC1 gene as a novel prognostic marker of hepatocellular carcinoma.
Shimizu D; Kanda M; Nomoto S; Oya H; Takami H; Hibino S; Suenaga M; Inokawa Y; Hishida M; Takano N; Nishikawa Y; Yamada S; Fujii T; Nakayama G; Sugimoto H; Koike M; Fujiwara M; Kodera Y
Oncol Rep; 2014 Mar; 31(3):1305-13. PubMed ID: 24366000
[TBL] [Abstract][Full Text] [Related]
10. Expression of hepatoma-derived growth factor in hepatocellular carcinoma.
Hu TH; Huang CC; Liu LF; Lin PR; Liu SY; Chang HW; Changchien CS; Lee CM; Chuang JH; Tai MH
Cancer; 2003 Oct; 98(7):1444-56. PubMed ID: 14508832
[TBL] [Abstract][Full Text] [Related]
11. INK4a-ARF alterations and p53 mutations in hepatocellular carcinomas.
Tannapfel A; Busse C; Weinans L; Benicke M; Katalinic A; Geissler F; Hauss J; Wittekind C
Oncogene; 2001 Oct; 20(48):7104-9. PubMed ID: 11704835
[TBL] [Abstract][Full Text] [Related]
12. DNA methylation markers and serum α-fetoprotein level are prognostic factors in hepatocellular carcinoma.
Lin JC; Wu YC; Wu CC; Shih PY; Wang WY; Chien YC
Ann Hepatol; 2015; 14(4):494-504. PubMed ID: 26019036
[TBL] [Abstract][Full Text] [Related]
13. Epigenetic silencing of Klotho expression correlates with poor prognosis of human hepatocellular carcinoma.
Xie B; Zhou J; Yuan L; Ren F; Liu DC; Li Q; Shu G
Hum Pathol; 2013 May; 44(5):795-801. PubMed ID: 23123137
[TBL] [Abstract][Full Text] [Related]
14. Clinical utility of PDSS2 expression to stratify patients at risk for recurrence of hepatocellular carcinoma.
Kanda M; Sugimoto H; Nomoto S; Oya H; Shimizu D; Takami H; Hashimoto R; Sonohara F; Okamura Y; Yamada S; Fujii T; Nakayama G; Koike M; Fujiwara M; Kodera Y
Int J Oncol; 2014 Nov; 45(5):2005-12. PubMed ID: 25189544
[TBL] [Abstract][Full Text] [Related]
15. Aberrant methylation of EDNRB and p16 genes in hepatocellular carcinoma (HCC) in Taiwan.
Hsu LS; Lee HC; Chau GY; Yin PH; Chi CW; Lui WY
Oncol Rep; 2006 Feb; 15(2):507-11. PubMed ID: 16391877
[TBL] [Abstract][Full Text] [Related]
16. CHD5 a tumour suppressor is epigenetically silenced in hepatocellular carcinoma.
Zhao R; Wang N; Huang H; Ma W; Yan Q
Liver Int; 2014 Jul; 34(6):e151-60. PubMed ID: 24529164
[TBL] [Abstract][Full Text] [Related]
17. Silencing of GSTP1 gene by CpG island DNA hypermethylation in HBV-associated hepatocellular carcinomas.
Zhong S; Tang MW; Yeo W; Liu C; Lo YM; Johnson PJ
Clin Cancer Res; 2002 Apr; 8(4):1087-92. PubMed ID: 11948118
[TBL] [Abstract][Full Text] [Related]
18. Epigenetic changes induced by reactive oxygen species in hepatocellular carcinoma: methylation of the E-cadherin promoter.
Lim SO; Gu JM; Kim MS; Kim HS; Park YN; Park CK; Cho JW; Park YM; Jung G
Gastroenterology; 2008 Dec; 135(6):2128-40, 2140.e1-8. PubMed ID: 18801366
[TBL] [Abstract][Full Text] [Related]
19. Hypermethylation of FOXD3 suppresses cell proliferation, invasion and metastasis in hepatocellular carcinoma.
He G; Hu S; Zhang D; Wu P; Zhu X; Xin S; Lu G; Ding Y; Liang L
Exp Mol Pathol; 2015 Oct; 99(2):374-82. PubMed ID: 26112097
[TBL] [Abstract][Full Text] [Related]
20. [Correlation between epigenetic alterations in the insulin growth factor-II gene and hepatocellular carcinoma].
Dong ZZ; Yao DF; Wu W; Qiu LW; Yao NH; Yan XD; Yu DD; Chen J
Zhonghua Gan Zang Bing Za Zhi; 2012 Aug; 20(8):593-7. PubMed ID: 23207153
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
